Morten Hostrup holds a PhD and is a Postdoc specialized in integrated human physiology and pharmacology at the Respiratory Research Unit of Bispebjerg Hospital. Mortens research focuses on performance-enhancing effects of beta2-agonists (asthma medication) with respect to anti-doping. The research has contributed to the understanding of how beta2-agonists interact with skeletal muscle and how their effects in skeletal muscle affects performance in athletes.
Medication affects muscles
These effects include improved ion handling and increased breakdown of glycogen and production of lactate. Moreover, his research has showed that beta2-agonists enhance muscle force production and sprint ability. Morten Hostrup, furthermore, has contributed with research in doping control analysis of beta2-agonists, which has helped establish urine thresholds for beta2-agonists on the doping list. Much of the research is supported by the World Anti-doping Agency (WADA) and Anti-doping Denmark.
Currently, he is investigating physiological effects of long-term use of beta2-agonists with emphasis on their effects on muscle growth in skeletal and cardiac muscle tissue as well as on their effects on metabolism and insulin sensitivity. The research is conducted in close collaboration with the Institute of Sports Medicine, Department of Cardiology and Department of Clinical Physiology at Bispebjerg Hospital and with researchers from the Department of Nutrition, Exercise and Sports at the University of Copenhagen.